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What do I know about Parkinson’s 
Disease? 
Objectives 
• Describe a new approach to Parkinson’s 
disease. 
• Discuss the diagnostic criteria for Parkinson’s 
disease. 
• Compare conditions misdiagnosed as 
Parkinson’s disease.  
• List drug and non-drug therapies. 
• Provide recommendations for practice. 
 
 
 
 
 
 
Faces of Parkinsonism 
Parkinson’s Disease 
• Described by James Parkinson in 1817 
• Kampavata (tremor and akinesia) described in 
literature in India 4500-1000 B.C. 
• Prevalence of 1 to 2 million people in North 
America 
• Mortality is 2 to 5 times higher versus age-
matched controls 
• Age is the single most consistent risk factor 
Epidemiology 
• Occurs throughout the world, in all ethnic groups 
• Slight male predominance 
• Incidence 
–  Lowest among Asians and African blacks 
–  Highest among whites 
–  African blacks much lower than Afro-Americans 
–  Exponential increase between ages 65 and 90 
–  Only 5-10% of patients have symptoms before 
 age 40 (risk reduction with smoking) 
 
Genetics 
• Early studies of twins excluded genetic 
contribution 
• 1997 study found high concordance among 
monozygotic twins (one twin had young-
onset disease) 
• Linkage to chromosome 2p13 in six families 
Pathological Findings 
• Progressive death of selected but heterogeneous 
populations of neurons 
• Sites 
– Pars compacta of substantia nigra (dopaminergic) 
– Selected aminergic brain stem nuclei 
(Catecholaminergic and serotoninergic) 
– Nucleus basalis of Meynert (cholinergic) 
– Hypothalamus 
– Small cortical neurons 
– Olfactory bulb, sympathetic ganglia, and 
parasympathetic neurons in the gut 
Premotor Phase 
Aspecific non-motor 
symptoms: 
 
• Hyposmia 
• Constipation 
• Depression 
• Articular pain 
• Fatigue 
• Orthostatic 
Hypotension 
 
Frail “in situ”:  mean 10 years 
Diagnosis 
2 yr 
Clinically Evident (PD) 
Specific motor 
symptoms: 
 
• Bradykinesia  
(plus at least) 
 
• Rigidity 
• Tremor 
• Postural  
Instability 
 
Frail:  mean 10 years 
> 1 yr 
With Complications (PD-D) 
Aspecific non-motor 
symptoms, specific in 
the geriatric setting 
 
• Memory Impairment 
• Sleep Disorder 
• Acute Delirium 
• Nocturia 
• Dysphagia with 
pneumonia 
 
ADL-Disability:  mean 7 years 
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A New Multidisciplinary Approach for this Old Actor  
Braak’s Stage 1-2 
 locus coeruleus 
 dorsal IX/X nucleus 
 
Clinical Symptoms  
Premotor Phase: 
• Hyposmia 
• Constipation 
• Depression 
• Articular pain 
• Fatigue 
• Orthostatic hypotension 
Braak’s Stage 3-4 
 mesocortex 
 substantia nigra 
 locus coeruleus 
 dorsal IX/X nucleus 
 
Clinical Symptoms 
Clinically Evident (PD): 
• Bradykinesia  
(plus at least) 
 
• Rigidity 
• Tremor 
• Postural Instability 
Braak’s Stage 5-6 
 neocortex (sec. & prim.) 
 neocortex association 
 mesocortex 
 substantia nigra 
 locus coeruleus 
 dorsal IX/X nucleus 
 
Clinical Symptoms  
With Complications (PD-D): 
• Memory Impairment 
• Sleep Disorder 
• Acute Delirium 
• Nocturia 
• Dysphagia with pneumonia 

Diagnosis 
• No biologic marker to confirm the diagnosis 
• Underdiagnosis and incorrect diagnosis are 
common 
• Classic signs and symptoms - tremor, rigidity, 
bradykinesia and postural instability 
• Best differentiate from other parkinsonisms by: 
–  Asymmetry 
–  Resting tremor 
–  Good response to levodopa 
UK Parkinson’s Disease Society clinical 
criteria 
• Step 1       
 Bradykinesia     
 At least one of the following:  
  Rigidity     
  4-6 Hz rest tremor   
  Postural instability not caused by 
  primary visual, vestibular, cerebellar 
  or proprioceptive dysfunction  
UK criteria 
• Step 2       
 Exclude other causes of parkinsonism 
• Step 3: at least 3 of the following criteria: 
 Unilateral onset, rest tremor, progressive 
disorder, asymmetry primarily affecting side of 
onset, 70-100% response to levodopa, severe 
levodopa induced dyskinesia, levodopa 
response for 5 years or more, clinical course of 
10 years or more. 
Features suggestive of alternative 
diagnoses 
• Dementia preceding motor symptoms 
• In first 3 years: postural instability, freezing, 
hallucinations ( not related to medication) 
• Supranuclear gaze palsy (downward gaze) 
• Severe symptomatic dysautonomia 
• Documentation of plausible cause of 
parkinsonism ( focal brain lesion, neuroleptic)  
Conditions Misdiagnosed as 
Parkinson’s Disease 
• Essential tremor 
• Vascular parkinsonism  
• Drug-induced parkinsonism  
• Dementia with Lewy bodies  
• Atypical parkinsonism ( progressive 
supranuclear palsy, multisystem atrophy) 
Tremor 
• Resting tremor 
• 4-6 Hz 
• Prominent in hands 
• Absent in 25% 
Tremor 
Parkinson’s disease 
• Age at onset  55-75 yrs 
• Family Hx +/- 
• Frequency (Hz) 4-6 
• Characteristics: Sup-
pronation- asymmetric 
• Rest -> increase 
• Writing dec. (micrographia) 
• Face, jaw, lips, chin 
Essential tremor 
• 10-80 years 
• Family Hx ++ 
• Hz 5-10 
• Flexion-extension- 
symmetric 
• Rest -> decrease 
• Increases (tremulous) 
• Head, voice 
Rigidity 
• Increased tone 
throughout range  
of motion 
• Increases when limbs 
are moving 
• By itself, not disabling 
• Spasticity versus rigidity 
Bradykinesia 
• One of the more disabling symptoms 
• Delay in starting all movements 
• Slowness and poverty of movement 
• Arrest of ongoing movements 
Postural Instability 
• Inability to maintain 
equilibrium 
• Inability to react to 
abrupt changes 
in position 
Modified Hoehn & Yahr Staging 
• Stage 0 = No signs of disease 
• Stage 1= Unilateral disease 
• Stage 1.5= Unilateral plus axial involvement 
• Stage 2= Bilateral disease ,no imbalance 
• Stage 2.5= Mild bilateral, recovery on pull test 
• Stage 3= postural instability but independent 
• Stage 4= Severe disability; still able to walk 
• Stage 5= Wheelchair or bed bound. 
Treatment of Parkinson’s Disease 
Decision to Start Medical Therapy 
(consider) 
• Effect of disease on dominant hand 
• Significant bradykinesia or gait disturbance 
• Personal philosophy regarding drug use 
• DEGREE TO WHICH DISEASE EFFECTS 
FUNCTION 
Protective Therapy 
• No proven treatment to slow progression 
• Selegiline-ameliorated symptoms/question 
of increased mortality 
• High dose Vitamin E ineffective 
Symptomatic Therapy 
• Levodopa remains the most 
effective treatment (Sinemet 
25/100 TID) 
–  Most patients benefit 
over the entire  
 course of the illness 
–  No evidence that it 
accelerates the  
 neuro-degenerative 
process 
–  Increases life expectancy 
–  Survival reduced if drug 
is delayed until 
 greater disability 
 
Symptomatic Therapy 
• Anticholinergics (Artane 0.5-1 mg BID) 
• Amantadine (100 mg BID) 
• Selegiline (5 mg BID - last dose mid-day)
 (rasagiline 1 mg daily) 
–  All have mild to moderate benefit, but    
 levodopa or dopamine agonists are 
 required as disability progresses 
• Tolcapone (COMT inhibitor) 100 mg TID  
monitor LFT’s 
Symptomatic 
Therapy 
 
Dopamine agonists 
 May provide 
inadequate benefit  
 (1/3 of patients 
have good 
responses) 
 Always require 
supplementary  
 levodopa but may 
be adequate alone 
 for two to five 
years 
 Infrequent 
fluctuations and 
dyskinesias 
Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease:  A 4-Year Randomized Controlled Trial Arch Neurol. 2004;61(7):1044-1053. 
doi:10.1001/archneur.61.7.1044 
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Cumulative probability of reaching the first dopaminergic complication (A) and the individual complications wearing off (B), 
dyskinesias (C), and freezing (D) by treatment assignment. First dopaminergic complication is defined as the first occurrence of 
wearing off, dyskinesias, or on-off fluctuations.  
 
Figure Legend: 
Pramipexole versus levodopa complications 
Dopamine Agonists 
Ergot-derived (lung and cardiac valve fibrosis) 
 Bromocriptine 20-40 mg/day 
Non-Ergot-derived (as first-line and adjunctive 
therapy) 
 Ropinirole up to 24 mg/day,   
   divided TID or SR 
 Pramipexole up to 4.5 mg/day,   
   divided TID or SR   
 Rotigotine up to 6 mg/24 hr patch 
 
Late Stage Problems  
(Disease) 
• Motor-dysarthria, freezing of gait, postural 
instability with falls 
• Nonmotor-dysautonomia, weight loss,  
pain, changes in mood or behavior,  
sleep disturbance, cognitive dysfunction, 
dementia 
Late Stage Problems  
(Treatment and Disease) 
Motor fluctuations:  (in 70% treated for 15 years) 
 • Wearing off of drug effect 
 • On-off phenomenon 
Dyskinesia:  (may respond to amantadine) 
 • Peak-dose dyskinesia 
 • Diphasic dyskinesia 
 • Off-period dystonia 
Psychiatric disturbances - vivid dreams, visual 
hallucinations, mania, hypersexuality, paranoid 
psychosis  
 
Surgical Candidate 
Surgical Therapy 
• Reserved for disabling, medically refractory 
symptoms 
• Ventrointermediate thalamic nucleus lesions 
reduce contralateral arm tremor by 80% 
• Pallidotomy - 80% improvement in contralateral 
drug-induced dyskinesia (akinesia, rigidity and 
tremor reduced) 
• Stimulation of subthalamic nuclei-benefits all 
aspects of parkinsonism 
Deep Brain Stimulation 
• For intolerable dyskinesias or motor 
fluctuation while on levodopa 
• Appropriate candidates have cognition 
relatively intact and are less than 70 yrs old. 
• Benefit: reduction in levodopa dose, 
improvement in off-medication function and 
reduced dyskinesias when taking medication. 
• Risks: depression, decreased verbal fluency, 
increased falls and impulsivity. 
Fetal Cell transplantation 
• 2 patients 
• Intrastriatal grafts of human fetal ventral 
mesencephalic tissue (dopaminergic 
neuroblasts) 
• Assessed 15 & 18 years post graft. 
 *motor gains over first yr. sustained 18yrs.
 *patient remained off dopaminergic drugs. 
Kefalopoulou Z et al, JAMA Neurol. 2013.4749 
 
 
Non-Medical Functional Assistance 
Support Services 
• Usual Elder Services 
• Specific Disease Oriented Organization 
 http://www.ninds.nih.gov/disorders/parkinso
ns_disease/org_parkinsons_disease.htm 
• Physical therapy – disability improves 
• Occupational therapy- in home interventions 
• Speech therapy- intensive therapy for 2 week can 
improve voice problems and gain may last up to 3 
months.  
 
 
 
 
 
Assisted Devices 
 


 
Recommendations for Practice 
• Carbidopa/levodopa, nonergot dopamine 
agonists, or MAOB-I for initial treatment. 
• Nonergot dopamine agonists, COMT-I or 
MAOB-I added to levodopa to treat motor 
complications. 
 
 
• Consistent, good-quality patient-oriented 
evidence. 
Recommendations for Practice 
• Amantadine for dyskinesias in advanced 
disease. 
• Deep brain stimulation for functional 
impairment despite optimal medical tx. 
• PT to improve gait and speech therapy to 
improve speech volume. 
 
• Inconsistent patient-oriented evidence. 
Recommendations for Practice 
• Physicians with limited experience should 
refer patients to confirm diagnosis. 
• OT may help patients maintain family, social 
and work roles, continue ADLs and improve 
safety. 
 
• Consensus, usual practice, expert opinion, 
case series. 
Dementia and Depression 
Caregiver burden Isolation and Loneliness  
Diagnosis 
2 yr > 1 yr 
Premotor Phase Clinically Evident (PD) With Complications (PD-D) 
Aspecific non-motor 
symptoms: 
 
• Hyposmia 
• Constipation 
• Depression 
• Articular pain 
• Fatigue 
• Orthostatic 
Hypotension 
 
Specific motor 
symptoms: 
 
• Bradykinesia  
(plus at least) 
 
• Rigidity 
• Tremor 
• Postural  
Instability 
 
Aspecific non-motor 
symptoms, specific in 
the geriatric setting 
 
• Memory Impairment 
• Sleep Disorder 
• Acute Delirium 
• Nocturia 
• Dysphagia with 
pneumonia 
 
Frail “in situ”:  mean 10 years Frail:  mean 10 years ADL-Disability:  mean 7 years 
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Question? 
Screening Tests 
• University on Penn Smell Identification Test 
(UPSIT)- (questionable accuracy) 
• SPECT 
• PET – (expensive) 
• Genetic tests – parkin gene (small fraction of PD) 
• Dopamine transporter scan (DaT scan) essential 
tremor vs PD 
• Voice change.    
 
